Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202859 | 0.99 | ADORA1 (0.37) | ADORA1MAPTKDM4EALOX15MEN1 | |
| SCHEMBL17318442 | 0.99 | ADORA1 (0.37) | ADORA1MAPTKDM4EALOX15MEN1 | |
| SCHEMBL12592486 | 0.99 | ADORA1 (0.37) | ADORA1MAPTKDM4EALOX15MEN1 | |
| SCHEMBL1957632 | 0.97 | ADORA1 (0.38) | ADORA1MAPTKDM4EALOX15MEN1 | |
| SCHEMBL18988666 | 0.85 | MAPT (0.35) | ADORA1MAPTKDM4EALOX15MEN1 | |
| SCHEMBL6492100 | 0.84 | KDM4E (0.36) | MAPTKDM4EALOX15MEN1KMT2A | |
| SCHEMBL6492089 | 0.84 | KDM4E (0.36) | MAPTKDM4EALOX15MEN1KMT2A | |
| SCHEMBL21332345 | 0.84 | MAPT (0.37) | ADORA1MAPTKDM4EALOX15MEN1 | |
| SCHEMBL4548472 | 0.84 | SLC6A3 (0.39) | MAPTALDH1A1HSD17B10 | |
| SCHEMBL1958265 | 0.82 | SLC6A3 (0.41) | MAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217913-A2 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023061406-A1 | PARP INHIBITOR CONTAINING FUSED TRI-CYCLIC STRUCTURE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 微境生物医药科技(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| CN-113135848-A | Preparation method of mercaptoalkenol ester compound | 深圳市华先医药科技有限公司 | 2021-07-20 | — | — | CN | disclosed |
| EP-3666758-A1 | PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | AbbVie Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3164396-B1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-01-16 | — | — | EP | disclosed |
| US-10100043-B2 | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
| EP-0718285-B1 | Restricted 9-cis-retinoids | AMERICAN CYANAMID CO (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0997455-A1 | Restricted 9-cis retenoids | American Cyanamid Company (US) | 2000-05-03 | — | — | EP | disclosed |
| US-5968908-A | Restricted 9-cis retinoids | AMERICAN CYANAMID COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100043-B2 | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, MB, HBG2 | ADORA1 589/4885MAPT 4741/4885KDM4E 1743/4885 |
| US-20180251426-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | ADORA1 4667/4885MAPT 4105/4885KDM4E 3629/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ADORA1 3277/4885MAPT 4181/4885KDM4E 1701/4885 |
| US-20240217913-A2 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | ACR, ADCYAP1R1, GNPAT | ADORA1 1546/4885MAPT 3852/4885KDM4E 4537/4885 |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | PTGER4, PTGER1, PTGER3 | ADORA1 710/4885MAPT 4578/4885KDM4E 1756/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | ADORA1 27/4885MAPT 4050/4885KDM4E 3585/4885 |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | IL4, IL5, IL2 | ADORA1 224/4885MAPT 3734/4885KDM4E 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.